Some images has been designed using resources from Unsplash & Pixabay & Pexels & Freepik and some icons from Flaticon
跳到主要內容
全站搜尋
:::

何祥齡 (Ho, Hsiang-Ling)

何祥齡(Ho, Hsiang-Ling)圖 掛號

[簡介]

  • 學歷
    陽明大學 醫學生物技術暨檢驗學系 學士
    陽明大學 生化暨分子生物研究所 博士
  • 經歷
    現職：
    • - 迄今 臺北榮民總醫院病理檢驗部 核心檢驗科 主任
    • - 迄今 國立陽明交通大學 醫學生物技術暨檢驗學系 兼任助理教授
    • - 迄今 台灣醫事檢驗學會 理事
    經歷：
    • - 中華民國醫事檢驗師公會全國聯合會 理事
    • - 臺北榮總病理檢驗部 分子病理科 組長
    • - 臺北榮總病理檢驗部 外科病理科 醫事檢驗師
    • - 臺北榮總病理檢驗部 博士後研究員
    • - 中央研究院生醫所 博士後研究員
  • 醫療專長
    1. 分子生物
    2. 生物醫學檢驗
    3. 實驗室品質管理
  • 證照
    衛生福利部 醫事檢驗師證書 (檢字第 012059號) 臺灣醫事檢驗學會分子領域專門醫事檢驗師證書 (醫檢分字第0025號)
  • 語言專長
    國語、台語、英語

[著作]

  1. Chiang CL, Ho HL, Yeh YC, Lee CC, Huang HC, Shen CI, et al. Prognosticators of osimertinib treatment outcomes in patients with EGFR-mutant non-small cell lung cancer and leptomeningeal metastasis. J Cancer Res Clin Oncol. 2022 Nov 1.
  2. Ho HL, Wang FY, Chiang CL, Tsai CM, Chiu CH, Chou TY. Dynamic Assessment of Tissue and Plasma EGFR-Activating and T790M Mutations with Droplet Digital PCR Assays for Monitoring Response and Resistance in Non-Small Cell Lung Cancers Treated with EGFR-TKIs. Int J Mol Sci. 2022 Sep 26;23(19):11353.
  3. Yeh YC, Ma HH, Chu PY, Ho HL, Chou TY. Programmed Death-Ligand 1 Expression in Lymphovascular Tumor Emboli in Lung Cancer. JTO Clin Res Rep. 2022 Jul;3(7):100349.
  4. Chang WC, Yeh YC, Ho HL, Chou TY. Deep exploration of immune function in EGFR wild-type and mutated lung adenocarcinomas by gene expression profiling: role of TRAIL-R2 (TNFRSF10B) in patient treatment and outcome. Hum Pathol. 2022 Aug;126:9–18.
  5. Lee HR, Wang FY, Li JL, Chou TY, Ho HL. Real-world Evaluation of a Sample Pooling Strategy for Large-Scale Rapid COVID-19 Testing. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2022 Apr;149:105133.
  6. Ho HL, Jiang Y, Chiang CL, Karwowska S, Yerram R, Sharma K, et al. Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer. PloS One. 2022;17(4):e0267362.
  7. Chang YH, Yang HJ, Chen HW, Hsiao CW, Hsieh YC, Chan YW, et al. Characterization of Collapsin Response Mediator Protein 2 in Colorectal Cancer Progression in Subjects with Diabetic Comorbidity. Cells. 2022 Feb 18;11(4):727.
  8. Lin YY, Wang YC, Yeh DW, Hung CY, Yeh YC, Ho HL, et al. Gene Expression Profile in Primary Tumor Is Associated with Brain-Tropism of Metastasis from Lung Adenocarcinoma. Int J Mol Sci. 2021 Dec 13;22(24):13374.
  9. Ho HL, Lin YY, Wang FY, Wu CH, Lee CL, Chou TY. Establishing diagnostic algorithms for SARS-CoV-2 nucleic acid testing in clinical practice. J Chin Med Assoc JCMA. 2021 Dec 1;84(12):1120–5.
  10. Yeh YC, Ho HL, Lin CI, Chou TY, Wang YC. Whole-exome Sequencing of Epstein-Barr Virus-associated Pulmonary Carcinoma With Low Lymphocytic Infiltration Shows Molecular Features Similar to Those of Classic Pulmonary Lymphoepithelioma-like Carcinoma: Evidence to Support Grouping Together as One Disease Entity. Am J Surg Pathol. 2021 Nov 1;45(11):1476–86.
  11. Chen PL, Hsiao YH, Chuang C, Feng JY, Ho HL, Lin YT, et al. The clinical manifestations and interval changes of reverse-transcriptase quantitative polymerase chain reactions among different specimens of coronavirus disease 2019 patients. J Chin Med Assoc JCMA. 2021 Feb 1;84(2):151–7.
  12. Lin SY, Hang JF, Lin YY, Lai CR, Ho HL, Chou TY. Diffuse Intratumoral Stromal Inflammation in Ovarian Clear Cell Carcinoma is Associated With Loss of Mismatch Repair Protein and High PD-L1 Expression. Int J Gynecol Pathol Off J Int Soc Gynecol Pathol. 2021 Mar 1;40(2):148–55.
  13. Wang LC, Lin TC, Yeh YC, Ho HL, Tsai CC, Chou TY. Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents. Curr Oncol Tor Ont. 2021 Feb 16;28(1):918–27.
  14. Lin YY, Lin LY, Hang JF, Lin CH, Ho HL, Chou TY. Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients. Cancer Cytopathol. 2021 Feb;129(2):148–55.
  15. Ho HL, Wang FY, Lee HR, Huang YL, Lai CL, Jen WC, et al. Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients. Lancet Reg Health West Pac. 2020 Oct;3:100041.
  16. Yeh YC, Ho HL, Wu YC, Pan CC, Wang YC, Chou TY. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Mod Pathol Off J U S Can Acad Pathol Inc. 2020 Mar;33(3):391–403.
  17. Shen CI, Ho HL, Yeh YC, Chiu CH, Chou TY. Epidermal growth factor receptor mutations in non-small cell lung cancer undetected by high-sensitivity allele-specific real-time polymerase chain reaction-based assays. J Chin Med Assoc JCMA. 2020 Apr;83(4):345–9.
  18. Wang ML, Hsu YF, Liu CH, Kuo YL, Chen YC, Yeh YC, et al. Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression. Int J Mol Sci. 2020 Sep 17;21(18):6829.
  19. Ho HL, Chou TY, Yang SH, Jiang JK, Chen WS, Chao Y, et al. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. J Cancer Res Clin Oncol. 2019 Jul;145(7):1785–94.
  20. Chen YY, Ho HL, Lin SC, Hsu CY, Ho DMT. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma. Neurosurgery. 2019 Sep 1;85(3):335–42.
  21. Chang WC, Yeh YC, Ho HL, Hsieh SL, Chou TY. Decoy Receptor 3 Expression Is Associated With Wild-Type EGFR Status, Poor Differentiation of Tumor, and Unfavorable Patient Outcome. Am J Clin Pathol. 2019 Jul 5;152(2):207–16.
  22. Lin CS, Huang YY, Pan SC, Cheng CT, Liu CC, Shih CH, et al. Involvement of increased p53 expression in the decrease of mitochondrial DNA copy number and increase of SUVmax of FDG-PET scan in esophageal squamous cell carcinoma. Mitochondrion. 2019 Jul;47:54–63.
  23. Yeh YC, Kao HL, Lee KL, Wu MH, Ho HL, Chou TY. Epstein-Barr Virus-Associated Pulmonary Carcinoma: Proposing an Alternative Term and Expanding the Histologic Spectrum of Lymphoepithelioma-like Carcinoma of the Lung. Am J Surg Pathol. 2019 Feb;43(2):211–9.
  24. Ho HL, Huang CC, Ku WH, Ho CL, Lin CH, Yu SL, et al. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan. J Chin Med Assoc JCMA. 2019 Jun;82(6):473–6.
  25. Ho HL, Kao HL, Yeh YC, Chou TY. The importance of EGFR mutation testing in squamous cell carcinoma or non-small cell carcinoma favor squamous cell carcinoma diagnosed from small lung biopsies. Diagn Pathol. 2019 Jun 21;14(1):59.
  26. Tseng YH, Ho HL, Lai CR, Luo YH, Tseng YC, Whang-Peng J, et al. PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2018 Mar;13(3):447–53.
  27. Chen YY, Ho HL, Lin SC, Ho TDH, Hsu CY. Upregulation of miR-125b, miR-181d, and miR-221 Predicts Poor Prognosis in MGMT Promoter-Unmethylated Glioblastoma Patients. Am J Clin Pathol. 2018 Mar 29;149(5):412–7.
  28. Lin YC, Lin CH, Yeh YC, Ho HL, Wu YC, Chen MY, et al. High O-linked N-acetylglucosamine transferase expression predicts poor survival in patients with early stage lung adenocarcinoma. Oncotarget. 2018 Jul 24;9(57):31032–44.
  29. Yang CF, Ho HL, Lin SC, Hsu CY, Ho DMT. Detection of human cytomegalovirus in glioblastoma among Taiwanese subjects. PloS One. 2017;12(6):e0179366.
  30. Hsu CY, Ho HL, Lin SC, Chen MH, Hsu SPC, Yen YS, et al. Comparative Assessment of 4 Methods to Analyze MGMT Status in a Series of 121 Glioblastoma Patients. Appl Immunohistochem Mol Morphol AIMM. 2017 Aug;25(7):497–504.
  31. Hsu CY, Ho HL, Lin SC, Ho TDH, Ho DMT. The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma. PloS One. 2017;12(10):e0186430.
  32. Chiang CL, Wang LC, Ho HL, Tsai CM, Yeh YC, Hsu WH, et al. Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy. Oncotarget. 2018 Jan 12;9(4):5435–44.
  33. Yeh YC, Lei HJ, Chen MH, Ho HL, Chiu LY, Li CP, et al. C-Reactive Protein (CRP) is a Promising Diagnostic Immunohistochemical Marker for Intrahepatic Cholangiocarcinoma and is Associated With Better Prognosis. Am J Surg Pathol. 2017 Dec;41(12):1630–41.
  34. Kao HL, Yeh YC, Lin CH, Hsu WF, Hsieh WY, Ho HL, et al. Diagnostic algorithm for detection of targetable driver mutations in lung adenocarcinomas: Comprehensive analyses of 205 cases with immunohistochemistry, real-time PCR and fluorescence in situ hybridization methods. Lung Cancer Amst Neth. 2016 Nov;101:40–7.
  35. Kao HL, Lai CR, Ho HL, Pan CC. Molecular typing for detection of high-risk human papillomavirus is a useful tool for distinguishing primary bladder carcinoma from secondary involvement of uterine cervical carcinoma in the urinary bladder. Histopathology. 2016 Mar;68(4):513–9.
  36. Hsu CY, Ho HL, Chang-Chien YC, Chang YW, Ho DMT. MGMT promoter methylation in non-neoplastic brain. J Neurooncol. 2015 Feb;121(3):459–67.
  37. Hsu CY, Ho HL, Lin SC, Chang-Chien YC, Chen MH, Hsu SPC, et al. Prognosis of glioblastoma with faint MGMT methylation-specific PCR product. J Neurooncol. 2015 Mar;122(1):179–88.
  38. Chiu CH, Ho HL, Doong H, Yeh YC, Chen MY, Chou TY, et al. MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma. Oncotarget. 2015 Apr 10;6(10):8407–17.
  39. Luo YH, Ho HL, Tsai CM, Shih JF, Chiu CH, Lai SL, et al. The association between tumor epidermal growth factor receptor (EGFR) mutation and multiple primary malignancies in patients with adenocarcinoma of the lungs. Am J Clin Oncol. 2015 Apr;38(2):147–51.
  40. Chiu CH, Ho HL, Chiang CL, Lin SF, Ma HH, Chuang YT, et al. Clinical characteristics and treatment outcomes of lung adenocarcinomas with discrepant EGFR mutation testing results derived from PCR-direct sequencing and real-time PCR-based assays. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer. 2014 Jan;9(1):91–6.
  41. Hsu CY, Yang CF, Liao LR, Ho HL, Ho DMT. Tonsil surface epithelium is ideal for monitoring Ki-67 immunohistochemical staining. Histopathology. 2013 Dec;63(6):810–6.
  42. Hsu CY, Lin SC, Ho HL, Chang-Chien YC, Hsu SPC, Yen YS, et al. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Am J Surg Pathol. 2013 Feb;37(2):264–71.
  43. Ho HL, Chang FP, Ma HH, Liao LR, Chuang YT, Chang-Chien YC, et al. Molecular diagnostic algorithm for epidermal growth factor receptor mutation detection in Asian lung adenocarcinomas: comprehensive analyses of 445 Taiwanese patients with immunohistochemistry, PCR-direct sequencing and Scorpion/ARMS methods. Respirol Carlton Vic. 2013 Nov;18(8):1261–70.
  44. Ho HL, Lee HY, Liao HC, Chen MY. Involvement of Saccharomyces cerevisiae Avo3p/Tsc11p in maintaining TOR complex 2 integrity and coupling to downstream signaling. Eukaryot Cell. 2008 Aug;7(8):1328–43.
  45. Ho HL, Shiau YS, Chen MY. Saccharomyces cerevisiaeTSC11/AVO3 participates in regulating cell integrity and functionally interacts with components of the Tor2 complex. Curr Genet. 2005 May;47(5):273–88.
回到最上